Table 2.

bivariate associations between selected clinical variables and type of polypill equivalent, CoLaus study, Lausanne, Switzerland, 2009–2012 and 2014–2017.

	2009–2012				2014–2017
	A	B	C	D	A	B	C	D
Gender
Woman	97 (3.6)	119 (4.4)	46 (1.7)	12 (0.5)	119 (4.7)	128 (5.1)	59 (2.3)	15 (0.6)
Man	182 (7.8)	144 (6.1)	81 (3.5)	28 (1.2)	204 (9.9)	138 (6.7)	84 (4.1)	22 (1.1)
p-value	< 0.001	0.006	< 0.001	0.003	< 0.001	0.021	0.001	0.077
Age group
[40–50]	16 (1.1)	13 (0.9)	9 (0.6)	3 (0.2)	6 (1.1)	3 (0.5)	1 (0.2)	1 (0.2)
[50–60]	44 (2.9)	50 (3.3)	25 (1.6)	8 (0.5)	37 (2.5)	38 (2.6)	11 (0.8)	1 (0.1)
[60–70]	101 (7.5)	118 (8.8)	43 (3.2)	8 (0.6)	83 (6.8)	74 (6.1)	34 (2.8)	10 (0.8)
[70+]	118 (16.0)	82 (11.1)	50 (6.8)	21 (2.9)	197 (14.7)	151 (11.3)	97 (7.2)	25 (1.9)
p-value	< 0.001	< 0.001	< 0.001	< 0.001§	< 0.001	< 0.001	< 0.001	< 0.001§
Smoking status
Never	72 (3.6)	103 (5.1)	40 (2.0)	8 (0.4)	81 (4.6)	107 (6.0)	46 (2.6)	11 (0.6)
Former	155 (8.3)	113 (6.0)	62 (3.3)	23 (1.2)	158 (9.3)	99 (5.9)	57 (3.4)	16 (1.0)
Current	51 (4.7)	47 (4.3)	25 (2.3)	9 (0.8)	61 (7.7)	38 (4.8)	25 (3.1)	5 (0.6)
p-value	< 0.001	0.125	0.026	0.014	< 0.001	0.430	0.386	0.483
History of CVD
No	192 (3.9)	242 (5.0)	97 (2.0)	29 (0.6)	173 (4.1)	217 (5.1)	103 (2.4)	21 (0.5)
Yes	87 (52.7)	21 (12.7)	30 (18.2)	11 (6.7)	150 (43.6)	49 (14.2)	40 (11.6)	16 (4.7)
p-value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

Results are expressed as number (row percentage). Equivalent A: aspirin + statin + any antihypertensive; equivalent B: no aspirin + statin + any antihypertensive; equivalent C: no aspirin + statin + calcium channel blocker; equivalent D: no aspirin + statin + calcium channel blocker + angiotensin-converting enzyme inhibitor. Between-group comparisons performed using chi-square or Fisher’s exact test (§).